|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01099 SINOPHARM
Nominal 
18.420 -0.040 (-0.217%) | 2024/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Turnover | 584,507,930 | -2.022% | 596,569,565 | 552,147,550 | 521,051,235 | 456,414,611 |
| Cost of Sales | (540,252,540) | -1.424% | (548,057,887) | (504,713,490) | (477,000,627) | (416,091,300) |
| Gross Profit | 44,255,390 | -8.774% | 48,511,678 | 47,434,060 | 44,050,608 | 40,323,311 |
| 2024/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | -- | -- | -- | -- | (598,478) | (750,224) | |
| Profit / (Loss) on Disposal | (1,582,079) | -23.488% | (2,067,764) | (1,936,170) | (1,130,821) | (1,273,561) | |
| Other Non-operating Items | (1,058,658) | -- | 625,967 | 82,278 | (375,813) | (202,327) | |
| Share of Results of Asso. & JCEs | 1,199,396 | 8.312% | 1,107,349 | 1,067,067 | 1,069,868 | 987,463 | |
| Profit / (Loss) before Taxation | 14,000,899 | -28.245% | 19,512,137 | 18,563,819 | 17,003,162 | 15,598,096 | |
| Taxation | (3,577,305) | -20.545% | (4,502,309) | (4,218,377) | (3,938,389) | (3,500,805) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | (3,373,911) | -43.353% | (5,956,068) | (5,819,787) | (5,306,127) | (4,910,013) | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 7,049,683 | -22.135% | 9,053,760 | 8,525,655 | 7,758,646 | 7,187,278 | |
| 2024/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Net Finance Costs / (Income) | 2,328,242 | -4.202% | 2,430,374 | 3,189,992 | 3,402,869 | 2,944,189 |
| Depreciation & Amortisation | 4,733,692 | 6.849% | 4,430,248 | 4,165,019 | 3,922,058 | 3,597,114 |
| Directors' Emoluments | -- | -- | 14,991 | 14,516 | 15,277 | 21,942 |
| 2024/12 - Final | %Chg (Compare to Final) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| Auditor's Opinion Status | Unqualified | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2024/12 - Final | %Chg (Compare to Final) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| EPS (cts) | 226.000 | -22.069% | 290.000 | 273.000 | 249.000 | 231.000 |
| DPS (cts) | 68.000 | -- | 87.000 | 82.000 | 75.000 | 69.000 |
| Dividend Payout Ratio (%) | 30.088% | -- | 30.000% | 30.037% | 30.120% | 29.870% |
| Cash flow per share ($) | 3.704 | -- | 5.510 | 6.726 | 2.983 | 3.585 |
| NBV per share ($) | 25.278 | -- | 23.900 | 21.812 | 19.831 | 18.060 |
| Remarks: | Real time quote last updated: 15/05/2025 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 7,049,683 |
| %Change | -22.135% |
| EPS / (LPS) | RMB 2.260 |
| NBV Per Share (¥) | RMB 25.278 |